My news for Investors

AtLeast one of the check box should be selected You are following news about Follow the latest news about MYL

    PITTSBURGH, March 23 /PRNewswire-FirstCall/ -- Mylan Laboratories Inc.
 (NYSE:   MYL) today launched Amlodipine Besylate Tablets, 2.5 mg (base), 5 mg
 (base) and 10 mg (base). Amlodipine Besylate Tablets are the generic
 version of Pfizer's Norvasc(R) Tablets, which had U.S. sales of
 approximately $2.7 billion for the 12-month period ended December 31, 2006,
 according to IMS Health. Mylan was the first generic company to file on all
 strengths of amlodipine and therefore has triggered its 180 days of
 exclusivity. The U.S. Court of Appeals for the Federal Circuit in
 Washington ruled yesterday that the last remaining patent in place for
 amlodipine besylate is invalid.
     Mylan Laboratories Inc. is a leading pharmaceutical company with three
 principal subsidiaries, Mylan Pharmaceuticals Inc., Mylan Technologies Inc.
 and UDL Laboratories Inc., and a controlling interest in Matrix
 Laboratories Limited, India. Mylan develops, licenses, manufactures,
 markets and distributes an extensive line of generic and proprietary
 products.
     For more information about Mylan, visit http://www.mylan.com.
     This press release includes statements that constitute "forward-looking
 statements," including with regard to the launch of Amlodipine Besylate
 Tablets and the duration of market exclusivity. These statements are made
 pursuant to the safe harbor provisions of the Private Securities Litigation
 Reform Act of 1995. Because such statements inherently involve risks and
 uncertainties, actual future results may differ materially from those
 expressed or implied by such forward- looking statements. Factors that
 could cause or contribute to such differences include, but are not limited
 to: the use of legal, regulatory and legislative strategies by competitors
 or other third parties to delay or prevent product introductions; risks
 inherent in legal proceedings; and the other risks detailed in the
 Company's periodic filings with the Securities and Exchange Commission. The
 Company undertakes no obligation to update these statements for revisions
 or changes after the date of this release.
 
 

SOURCE Mylan Laboratories Inc.